Key result
Dual antiplatelet therapy fails to prevent acute heparin-induced thrombocytopenia and severe clinical sequelae.
Case Report (n=2)
Answers are grounded in this paper and cite their sources.
Platelet adenosine diphosphate (ADP) receptors may play a role in potentiating platelet activation induced by IgG from patients with immune heparin-induced thrombocytopenia (HIT), as shown by previous studies using the ADP receptor antagonists AR-C66096 and ticlopidine. Consistent with these observations, we found that platelet activation by HIT sera is also significantly reduced in patients receiving clopidogrel, an ADP receptor antagonist prodrug now in wide clinical use. Despite these in vitro and ex vivo findings, we observed two patients develop acute HIT while receiving both clopidogrel and aspirin: both patients' sera tested strongly positive in a heparin-dependent washed platelet activation assay (100% serotonin release) and PF4/heparin-enzyme-immunoassay (2.594 and 2.190 absorbance units). Both patients also developed HIT-associated clinical sequelae (acute systemic reaction postintravenous heparin bolus; thrombotic stroke) in association with their episode of HIT. We conclude that combined therapy with aspirin and clopidogrel does not necessarily protect against clinical HIT, at least in patients with HIT antibodies that have strong platelet-activating characteristics.
No takes yet. Share an insight, caveat, or question.
Selleng et al. (2005) conducted a case report in Heparin-induced thrombocytopenia (HIT) (n=2). Combined aspirin and clopidogrel therapy was evaluated on Development of acute HIT and HIT-associated clinical sequelae. Two patients developed acute heparin-induced thrombocytopenia with strong platelet-activating characteristics and clinical sequelae despite receiving combined aspirin and clopidogrel therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: